What date is the UK loss of exclusivity for Lantus?
The provided information does not include the specific UK “loss of exclusivity” date for Lantus. Without the underlying source (for example, an NHS Business Services/UK patent-exclusivity note, SPC/loss-of-exclusivity dossier, or a published regulatory filing that states the exact date), I can’t give a reliable date.
Why you may see different “dates” for Lantus in the UK
Even when the drug and market are the same, “loss of exclusivity” can be reported as different event dates, depending on what someone is counting:
- Patent expiry (including potential adjustments or extensions)
- SPC expiry (if an SPC exists for the product)
- Regulatory/marketing exclusivity windows
- Tender or reimbursement-driven access timelines (separate from legal exclusivity)
What to check to get the exact UK date
To identify the correct loss-of-exclusivity date, you typically need one of these:
- The EMA/UK product authorization exclusivity data used by the UK (if available in your source)
- The UK SPC/patent register entries for Lantus (insulin glargine) and the relevant expiry dates
- A published “LOE/entry” dataset from a payer, regulator, or market-access source that states the specific UK date for biosimilar entry/LOE
If you want, I can pin down the date quickly
Share one of the following and I’ll compute/verify the exact UK LOE date from it:
- A link or screenshot to the page/dataset you’re using
- The exact product pack/strength you mean (e.g., 100 units/mL solution for injection), since LOE references can be product-specific
- Whether you mean legal LOE (patent/SPC) or a market-access LOE used by the NHS/tenders